Skip to Main Content

Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug to treat Alzheimer’s disease, taking advantage of the unprecedented regulatory path established by Biogen.

The pharma giant intends to submit its drug called donanemab to the Food and Drug Administration by the end of the year. Lilly will request the agency grant the drug accelerated approval based on its ability to reduce amyloid plaques in the brain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment